$SEPN News

Septerna to Participate in Upcoming Investor Conferences

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

JP Morgan Maintains Overweight on Septerna, Raises Price Target to $48

Jones Trading Maintains Buy on Septerna, Raises Price Target to $62

Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $50

HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $60

Guggenheim Maintains Buy on Septerna, Raises Price Target to $51

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Septerna Q2 EPS $(0.29) Beats $(0.43) Estimate, Sales $26.746M Beat $17.875M Estimate

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?

Guggenheim Maintains Buy on Septerna, Lowers Price Target to $45

HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target

Truist Securities Maintains Buy on Septerna, Raises Price Target to $43

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Septerna: A De-Risking GPCR Story With Near-Term Upside Catalysts

Raymond James Maintains Strong Buy on Septerna, Raises Price Target to $53

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna Announces First Detailed Preclinical Characterization Of SEP-479 Accepted For Oral Presentation At ENDO 2026